Transcode Therapeutics, Inc. (RNAZ) stock
Close on Nov 12, 2026Market cap $1.41MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.41M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$42.83M
- EPS, diluted
- -$52.59
- Free cash flow
- -$19.52M
- Book value per share
- -$28.93
- Diluted shares
- 1M
Trading
- Previous close
- $1.40
- Open
- $1.36
- Day's range
- $1.35 – $1.47
- Volume
- 13,940
- Average volume (20 days)
- 22,361
- Beta (5 years)
- 1.52
- 52-week range
- $1.33 – $12.60
- RSI (14 days)
- 35.0
- Volatility (1 year)
- 97.8%
- Relative volume
- 0.26×
- WACC
- 12.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | RNAZ | S&P 500 | Difference | RNAZ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.7% | -2.7% | −12.0 pts | ||
| 3 months | -58.7% | -1.7% | −57.0 pts | ||
| Year to date | -79.6% | +11.9% | −91.5 pts | ||
| 1 year | -84.2% | +12.0% | −96.2 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -95.2% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -94.2% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Transcode Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Update
- News
- Update
- Update
About Transcode Therapeutics
Pharmaceutical Preparations
TransCode is a clinical-stage biotechnology company that develops immuno-oncology and RNA-targeted therapeutics for the treatment of high-risk, advanced, and metastatic cancers. The company utilizes its proprietary TTX modular drug design engine to create delivery vehicles for synthetic oligonucleotides targeting genetic elements outside the liver. Its product candidates include TTX-MC138, an antisense inhibitor targeting microRNA-10b for solid tumors, alongside preclinical programs TTX-siPDL1, TTX-RIGA, and TTX-siMYC. Through acquisitions and licensing, TransCode also develops Seviprotimut-L, a polyvalent vaccine for stage IIB and IIC melanoma, and an oncolytic adenovirus immunotherapy platform directed at solid tumors including muscle-invasive bladder cancer. Its pipeline serves cancer patients with high unmet medical needs.
Company profile, executives and historyTranscode Therapeutics stock: common questions
What is Transcode Therapeutics's stock price?
RNAZ closed at $1.39 on Nov 12, 2026, down 0.69% on the day. Over the past 52 weeks it traded between $1.33 and $12.60.
What is Transcode Therapeutics's market cap?
Transcode Therapeutics was worth $1.41M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is RNAZ's P/E ratio?
Transcode Therapeutics lost money over fiscal 2025 (diluted EPS -$52.59), so it has no meaningful P/E ratio.
Does Transcode Therapeutics pay a dividend?
No. Transcode Therapeutics has not paid a cash dividend over the last twelve months.
How has RNAZ stock performed over the past year?
Including dividends, RNAZ returned -84.2% over the past year, against +12.0% for the S&P 500.
Who are Transcode Therapeutics's competitors?
Companies most similar to Transcode Therapeutics by business, industry and size include ELTX, IMNM, TOVX, IMRX, GNPX.
See a number that looks wrong?